Treat and extend paradigm in management of neovascular age-related macular degeneration: current practice and future directions

References

• Keel S, Xie J, Foreman J, et al. Prevalence of age-related macular degeneration in Australia. JAMA Ophthalmol. 2017;135(11):1242.
   PubMed Web of Science ®Google Scholar
• Jonasson F, Arnarsson A, Sasaki H, et al. The prevalence of age-related maculopathy in Iceland: reykjavik eye study. Arch Ophtalmol. 2003;121(3):379–385.
   PubMedGoogle Scholar
• Wang JJ, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2000;28(4):268–273.
   PubMed Web of Science ®Google Scholar
• Wilde C, Poostchi A, Mehta RL, et al. Prevalence of age-related macular degeneration in an elderly UK Caucasian population—The Bridlington eye assessment project: a cross-sectional study. Eye. 2017;31(7):1042–1050.
   PubMed Web of Science ®Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116.
   PubMed Web of Science ®Google Scholar
• Eyetech Study G. The Eyetech Study G. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina (Philadelphia, Pa). 2002;22(2):143–152.
   PubMed Web of Science ®Google Scholar
• Holz FG, Dugel PU, Weissgerber G, et al. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: a Randomized Controlled Study. Ophthalmology. 2016 May 01;123(5):1080–1089.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Bailey C, Brown D, et al. Phase I trial of anti-vascular endothelial growth factor/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration. Ophthalmol Retina. 2017;1(6):474–485.
   PubMedGoogle Scholar
• Souied EH, Devin F, Mauget-Faÿsse M, et al. Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2014 Oct;158(4):724–732.e2.
   PubMed Web of Science ®Google Scholar
• Liu K, Song Y, Xu G, et al. Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol. 2019;197:156–167.
   PubMed Web of Science ®Google Scholar
• Patel SS, Naor J, Qudrat A, et al. Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durability. Invest Ophthalmol Vis Sci. 2019;60(9):3670.
   Web of Science ®Google Scholar
• NCT03066258 CgI. Safety and tolerability of RGX-314 gene therapy for neovascular AMD trial. Clinicaltrials.gov. 2017.
   Google Scholar
• NCT0374878 CgI. ADVM-022 intravitreal gene therapy for wet AMD (OPTIC). Clinicaltrials.gov. Adverum Biotechnologies, Inc.; 2018.
   Google Scholar
• NCT03585556 CgI. AAVCAGsCD59 for the treatment of wet AMD. In: Biosciences H, editor. clinicaltrials.gov. 2018.
   Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444.
   PubMed Web of Science ®Google Scholar
• Busbee BG, Ho AC, Brown DM, et al. Twelve-Month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–1056.
   PubMed Web of Science ®Google Scholar
• Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181–2192.
   PubMed Web of Science ®Google Scholar
• Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175–1183.
   PubMed Web of Science ®Google Scholar
• Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150:315–24.e1.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009 Sept 01;116(9):1731–1739.
   PubMed Web of Science ®Google Scholar
• Heier JSMD, Brown DMMD, Chong VMD, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology (Rochester, Minn). 2012;119(12):2537–2548.
   PubMed Web of Science ®Google Scholar
• NCT03823287 CgI. A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (TENAYA). Clinicaltrials.gov. 2019.
   Google Scholar
• NCT04049266 CgI. A study to evaluate the efficacy and safety of KSI-301, an anti-VEGF antibody biopolymer conjugate, versus aflibercept in patients with neovascular (wet) age-related macular degeneration. (DAZZLE). 2019. Clinicaltrials.gov
   Google Scholar
• NCT04514653 CgI. RGX-314 gene therapy administered in the suprachoroidal space for participants with neovascular age-related macular degeneration (nAMD) (AAVIATE). Clinicaltrialsgov. 2020;Regenxbio Inc.
   Google Scholar
• Rodrigues GA, Mason M, Christie L-A, et al. Functional characterization of abicipar-pegol, an anti-VEGF DARPin therapeutic that potently inhibits angiogenesis and vascular permeability. Invest Ophthalmol. 2018;59(15):5836.
   Google Scholar
• Nori M, Basile A, Hutmacher M, et al. Population pharmacokinetics of pegaptanib sodium (Macugen®) in patients with diabetic macular edema. Clin Ophthalmol. 2015;323.
   PubMed Web of Science ®Google Scholar
• Michalska-Małecka K, Kabiesz A, Nowak M, et al. Age related macular degeneration – challenge for future: pathogenesis and new perspectives for the treatment. Eur Geriatric Med. 2015 Feb 01;6(1):69–75.
   Web of Science ®Google Scholar
• Spooner K, Mhlanga C, Hong T, et al. The burden of neovascular age-related macular degeneration: a patient’s perspective. Clin Ophthalmol. 2018;12:2483–2491.
   PubMed Web of Science ®Google Scholar
• Hanemoto T, Hikichi Y, Kikuchi N, et al. The impact of different anti-vascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese setting. PLOS ONE. 2017;12(12):e0189035.
   PubMed Web of Science ®Google Scholar
• Cascella R, Ragazzo M, Strafella C, et al. Age-related macular degeneration: insights into inflammatory genes. J Ophthalmol. 2014;2014:582842.
   PubMed Web of Science ®Google Scholar
• Fritsche LG, Loenhardt T, Janssen A, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet. 2008 Jul;40(7):892–896.
   PubMed Web of Science ®Google Scholar
• Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron. 2012 Jul 12;75(1):26–39.
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA, Negrão S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21(5):416–434.
   PubMed Web of Science ®Google Scholar
• Kwak N, Okamoto N, Wood JM, et al. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3158–3164.
   PubMed Web of Science ®Google Scholar
• Ying G-S, Maguire MG, Pan W, et al. Baseline predictors for five-year visual acuity outcomes in the comparison of AMD treatment trials. Ophthalmol Retina. 2018;2(6):525–530.
   PubMedGoogle Scholar
• Gragoudas ES. VEGF inhibition study in ocular neovascularization-1 (VISION=1): efficacy results from phase II/III MACUGENTM (Pegaptanib Sodium) Clinical Trials. IOVS. 2004;45. ARVO E‐abstract 2364.
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1982;100(6):912.
   Google Scholar
• Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol. Arch Ophtalmol. 1986;104(5):694.
   PubMedGoogle Scholar
• Macular photocoagulation study group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophtalmol. 1991;109(8):1109.
   PubMedGoogle Scholar
• Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina. 2004 Feb;24(1):1–12.
   PubMed Web of Science ®Google Scholar
• D’Amico DJ. Group VISiONCT. VEGF inhibition study in ocular neovascularization (VISION): second year efficacy data. Invest Ophthalmol Vis Sci. 2005;46(13):2309.
   Google Scholar
• Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125(11):1460–1469.
   PubMedGoogle Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388–1398.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Morescalchi F, Duse S, et al. Pharmacokinetic and pharmacodynamic properties of anti-VEGF drugs after intravitreal injection. Curr Drug Metab. 2015;16(7):572–584.
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009 Jan;116(1):57–65.e5.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537–2548.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth UMD, Eldem BMD, Guymer RMDP, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology (Rochester, Minn). 2011;118(5):831–839.
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006 Mar 01;113(3):363–372.e5.
   PubMed Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013 Nov;120(11):2292–2299.
   PubMed Web of Science ®Google Scholar
• Munk MR, Ceklic L, Ebneter A, et al. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol. 2016 Dec;94(8):e757–e764.
   PubMed Web of Science ®Google Scholar
• Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration. Ophthalmology. 2021;128(2):234–247.
   PubMed Web of Science ®Google Scholar
• Essex RW, Nguyen V, Walton R, et al. Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration. Ophthalmology (Rochester, Minn). 2016;123(11):2393–2400.
   PubMed Web of Science ®Google Scholar
• Silva R, Berta A, Larsen M, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration. Ophthalmology (Rochester, Minn). 2018;125(1):57–65.
   PubMed Web of Science ®Google Scholar
• Kertes PJ, Galic IJ, Greve M, et al. Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial. JAMA Ophthalmol. 2020;138(3):244–250.
   PubMed Web of Science ®Google Scholar
• Kertes PJ, Galic IJ, Greve M, et al. Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized canadian treat-and-extend analysis trial with ranibizumab study. Ophthalmology. 2019 Jun;126(6):841–848.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration. Ophthalmology. 2015;122(12):2514–2522.
   PubMed Web of Science ®Google Scholar
• NCT04005352 CgI. Study to assess the efficacy and safety of brolucizumab 6mg compared to aflibercept 2 mg in a treat-to-control regimen (TALON) (TALON). Clinicaltrials.gov. 2019.
   Google Scholar
• Gillies MC, Hunyor AP, Arnold JJ, et al. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2019 Apr 1;137(4):372–379.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Hunyor AP, Arnold JJ, et al. Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study). Ophthalmology. 2020 Feb;127(2):198–210.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–1411.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013 Oct 12;382(9900):1258–1267.
   PubMed Web of Science ®Google Scholar
• Wykoff CCMDP, Brown DMMD, Croft DEBA, et al. Two year SAVE outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. Ophthalmology (Rochester, Minn). 2013;120(9):1945–1946.e1.
   PubMed Web of Science ®Google Scholar
• Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150(3):315–324.e1.
   PubMed Web of Science ®Google Scholar
• Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239–248.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118:831–839.
   PubMed Web of Science ®Google Scholar
• Aurell S, Sjövall K, Paul A, et al. Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat‐and‐extend compared with pro re nata in eyes with neovascular age‐related macular degeneration. Acta Ophthalmol. 2019;97(5):519–524.
   PubMed Web of Science ®Google Scholar
• Amoaku W, Balaskas K, Cudrnak T, et al. Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group. Clin Ophthalmol. 2018;12:1731–1740.
   PubMed Web of Science ®Google Scholar
• Kim JH. Results of Switching from pro re nata to treat-and-extend regimen in treatment of patients with type 3 neovascularization. Semin Ophthalmol. 2019;35(1):33–40.
   Web of Science ®Google Scholar
• Yang Y, Downey L, Mehta H, et al. Resource use and real-world outcomes for ranibizumab treat and extend for neovascular age-related macular degeneration in the UK: interim results from TERRA. Ophthalmol Ther. 2017;6(1):175–186.
   PubMed Web of Science ®Google Scholar
• Jaki Mekjavia P, Gregorcic B, Oberc C, et al. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia. BMC Ophthalmol. 2018;18:1.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005 Jun;112(6):1048–1053.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2005;36(4):331–335.
   Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Visual Science. 2005;46:726–733.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmology Clinics of North America. 2006;19:361–372.
   PubMedGoogle Scholar
• Martin DF, Maguire MG, Ying G-S, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009 Nov;116(11):2141–8.e1.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020 Jan;127(1):72–84.
   PubMed Web of Science ®Google Scholar
• Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010;340(7761):1398.
   Google Scholar
• Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007 Apr;143(4):679–680. 2007 2015-01-14.
   PubMed Web of Science ®Google Scholar
• Mrejen S, Jung JJ, Chen C, et al. Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration. J Clin Med. 2015;4(7):1380–1402.
   PubMed Web of Science ®Google Scholar
• Berg K, Pedersen TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146–152.
   PubMed Web of Science ®Google Scholar
• Abedi MF, Wickremasinghe MS, Islam HAF, et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina. 2014;34(8):1531–1538.
   PubMed Web of Science ®Google Scholar
• Arnold JJ, Markey CM, Kurstjens NP, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration–a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016 Mar;24(16):31.
   Web of Science ®Google Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148(1):43–58.e1.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Lindsley KB, Krzystolik MG, et al. Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a cochrane systematic review. Ophthalmology. 2016 Jan;123(1):70–77.e1.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2020;127(4):S135–S145.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet (London, England). 2013;382:1258–1267.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Ou WC, Croft DE, et al. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol. 2018 Apr;102(4):460–464.
   PubMed Web of Science ®Google Scholar
• Calvo P, Wang Y, Ferreras A, et al. Treat and extend versus treat and observe regimens in wet age- related macular degeneration patients treated with ranibizumab: 3-year surveillance period. J Clin Exp Ophthalmol. 2014;5:1–5.
   Google Scholar
• Freund BK, Korobelnik BJ-F, Devenyi BR, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina. 2015;35(8):1489–1506.
   PubMed Web of Science ®Google Scholar
• Guymer RH, Markey CM, McAllister IL, et al. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019 May;126(5):723–734.
   PubMed Web of Science ®Google Scholar
• Barthelmes PD, Nguyen WV, Daien JV, et al. Two year outcomes of “treat and extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina. 2018;38(1):20–28.
   PubMed Web of Science ®Google Scholar
• Ohji M, Takahashi K, Okada AA, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020;37(3):1173–1187.
   PubMed Web of Science ®Google Scholar
• Spooner K, Fraser-Bell S, Hong T, et al. Long-term anti-VEGF treatment for neovascular age-related macular degeneration. The LATAR Study Report 1: ten-year, real-world outcomes. Ophthalmol Retina. 2020. DOI:10.1016/j.oret.2020.09.019.
   PubMedGoogle Scholar
• NCT02581891 CgI. Managing neovascular (known as “wet”) age-related macular degeneration over 2 years using different treatment schedules of 2 mg intravitreal aflibercept injected in the eye (ARIES). Clinicaltrialsgov. Bayer, Regeneron Pharmaceuticals; 2020
   Google Scholar
• Silva R, Berta A, Larsen M, et al. Treat-and-Extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology (Rochester, Minn). 2018;125(1):57–65.
   PubMed Web of Science ®Google Scholar
• Berg K, Roald AB, Navaratnam J, et al. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Acta Ophthalmol. 2017;95(8):796–802.
   PubMed Web of Science ®Google Scholar
• Arnold JJ, Campain A, Barthelmes D, et al. Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;122(6):1212–1219.
   PubMed Web of Science ®Google Scholar
• Koh A, Lanzetta P, Lee WK, et al. Recommended guidelines for use of intravitreal aflibercept with a treat-and-extend regimen for the management of neovascular age-related macular degeneration in the asia-pacific region: report from a consensus panel. Asia-Pac J Ophthalmol. 2017;6(3):296–302.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144–1167.
   PubMed Web of Science ®Google Scholar
• Abdin A, Suffo S, Asi F, et al. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration. Graefe’s Arch Clin Exp Ophthalmol. 2019;257(8):1671–1677.
   PubMed Web of Science ®Google Scholar
• Augsburger M, Sarra G-M, Imesch P. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefe’s Arch Clin Exp Ophthalmol. 2019;257(9):1889–1895.
   PubMed Web of Science ®Google Scholar
• Engelbert AM, Zweifel BS, Freund BK. Long-term Follow-up For Type 1 (subretinal pigment epithelium) Neovascularization using a Modified “Treat and Extend” Dosing Regimen of Intravitreal Endothelial Growth Factor Therapy. Retina. 2010;30(9):1368–1375.
   PubMed Web of Science ®Google Scholar
• Parke IDW, Lum F, Rich WL. The IRIS® Registry: purpose and perspectives. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2017;114(S1):1–6.
   PubMed Web of Science ®Google Scholar
• Holz FG, Figueroa MS, Bandello F, et al. Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study. Retina (Philadelphia, Pa). 2020;40(9):1673–1685.
   PubMed Web of Science ®Google Scholar
• Varano M, Eter N, Winyard S, et al. Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey. Clin Ophthalmol. 2015;2243.
   PubMedGoogle Scholar
• Berg K, Pedersen TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146–152.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results: comparison of age-related macular degeneration treatments trials (CATT) research group. Ophthalmology (Rochester, Minn). 2012;119(7):1388–1398.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015 Dec;122(12):2514–2522.
   PubMed Web of Science ®Google Scholar
• Roberts PK, Nesper PL, Gill MK, et al. Semiautomated quantitative approach to characterize treatment response in neovascular age-related macular degeneration. Retina. 2017;37(8):1492–1498.
   PubMed Web of Science ®Google Scholar
• Tran TH, Querques G, Forzy G, et al. Angiographic regression patterns after intravitreal ranibizumab injections for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2011 Nov-Dec;42(6):498–508.
   PubMedGoogle Scholar
• Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016 Jan;50:1–24.
   PubMed Web of Science ®Google Scholar
• Cabral D, Coscas F, Pereira T, et al. Quantitative optical coherence tomography angiography biomarkers in a treat-and-extend dosing regimen in neovascular age-related macular degeneration. Trans Vision Sci Technol. 2020;9(3):18.
   PubMed Web of Science ®Google Scholar
• Tan PL, Bowes Rickman C, Katsanis N. AMD and the alternative complement pathway: genetics and functional implications. Hum Genomics. 2016;10(1):23.
   PubMed Web of Science ®Google Scholar
• Edwards AO, Malek G. Molecular genetics of AMD and current animal models. Angiogenesis. 2007;10(2):119–132. 2014-08-30.
   PubMedGoogle Scholar
• Fritsche LG, Igl W, Bailey JNC, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134–143.
   PubMed Web of Science ®Google Scholar
• Grassmann F, Fauser S, Weber BHF. The genetics of age-related macular degeneration (AMD) – novel targets for designing treatment options? Eur J Pharm Biopharm. 2015;95(Pt B):194–202.
   PubMed Web of Science ®Google Scholar
• Abdelfattah NS, Al-Sheikh M, Pitetta S, et al. Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab. Ophthalmology (Rochester, Minn). 2017;124(2):215–223.
   PubMed Web of Science ®Google Scholar
• Spooner KL, Fraser-Bell S, Cozzi M, et al. Macular atrophy incidence and progression in eyes with neovascular age-related macular degeneration treated with vegf inhibitors using a treat-and-extend or a pro-re-nata regimen. four year results of the MANEX study. Ophthalmology. 2020;127:1663–1673.
   PubMed Web of Science ®Google Scholar
• Akwii RG, Sajib MS, Zahra FT, et al. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells (Basel, Switzerland). 2019;8(5):471.
   Google Scholar
• Stewart MW, Rosenfeld PJ, Penha FM, et al. harmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina (Philadelphia, Pa). 2012 Mar;32(3):434–457.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Boyer DS, Antoszyk AN, et al. Phase 1 study of OPT-302 inhibition of vascular endothelial growth factors C and D for neovascular age-related macular degeneration. Ophthalmol Retina. 2020 Mar;4(3):250–263.
   PubMedGoogle Scholar
• Rodrigues GA, Mason M, Christie LA, et al. Functional characterization of abicipar-pegol, an anti-VEGF DARPin therapeutic that potently inhibits angiogenesis and vascular permeability. Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5836–5846.
   PubMed Web of Science ®Google Scholar
• Kunimoto D, Yoon YH, Wykoff CC, et al. Efficacy and Safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study. Ophthalmology. 2020;127(10):1331–1344.
   PubMed Web of Science ®Google Scholar
• Hussain RM, Weng CY, Wykoff CC, et al. Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020;20(9):999–1008.
   PubMed Web of Science ®Google Scholar
• Khurana RN, Kunimoto D, Yoon YH, et al. Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age‐related macular degeneration. Ophthalmology. 2020. DOI:10.1016/j.ophtha.2020.11.017.
   Web of Science ®Google Scholar
• Kimura M, Kusuhara S, Tagami M, et al. Impaired retinal circulation during axitinib treatment for metastatic renal cell carcinoma. Case Rep Ophthalmol. 2019;10(1):5–10.
   PubMed Web of Science ®Google Scholar
• Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138(9):964–972.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology (Rochester, Minn). 2019;126(8):1141–1154.
   PubMed Web of Science ®Google Scholar
• Bhuiyan A, Wong TY, Ting DSW, et al. Artificial intelligence to stratify severity of age-related macular degeneration (AMD) and predict risk of progression to late AMD. Trans Vision Sci Technol. 2020;9(2):25.
   PubMed Web of Science ®Google Scholar
• Von Der Emde L, Pfau M, Dysli C, et al. Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration. Sci Rep. 2019;9:1.
   PubMed Web of Science ®Google Scholar
• Pead E, Megaw R, Cameron J, et al. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019;64(4):498–511.
   PubMed Web of Science ®Google Scholar
• Hwang D-K, Hsu -C-C, Chang K-J, et al. Artificial intelligence-based decision-making for age-related macular degeneration. Theranostics. 2019;9(1):232–245.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Waldstein SM, Klimscha S, et al. Prediction of Individual disease conversion in early AMD using artificial intelligence. Invest Ophthalmol. 2018;59(8):3199.
   Google Scholar
• NCT03823300 CgI. A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (LUCERNE). Clinicaltrials.gov. 2019.
   Google Scholar